NL192870C - Anti-hypertensief oraal farmaceutisch preparaat. - Google Patents

Anti-hypertensief oraal farmaceutisch preparaat. Download PDF

Info

Publication number: NL192870C
Authority: NL; Netherlands
Prior art keywords: day; hydrochlorothiazide; blood pressure; hours; administered
Prior art date: 1977-12-27

Application number

NL7812164A

Other languages

English (en)

Dutch (nl)

Other versions

NL192870B (nl

NL7812164A (nl

Original Assignee

Squibb & Sons Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-12-27

Filing date

1978-12-14

Publication date

1998-04-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25343256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL192870(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1978-12-14 Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc

1979-06-29 Publication of NL7812164A publication Critical patent/NL7812164A/xx

1997-12-01 Publication of NL192870B publication Critical patent/NL192870B/xx

1998-04-02 Application granted granted Critical

1998-04-02 Publication of NL192870C publication Critical patent/NL192870C/nl

Links

230000003276 anti-hypertensive effect Effects 0.000 title description 2
239000008183 oral pharmaceutical preparation Substances 0.000 title description 2
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 15
229960003883 furosemide Drugs 0.000 claims description 15
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 12
229960002003 hydrochlorothiazide Drugs 0.000 claims description 12
229960002429 proline Drugs 0.000 claims description 12
241000700159 Rattus Species 0.000 claims description 11
230000036772 blood pressure Effects 0.000 claims description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
150000001875 compounds Chemical class 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 7
206010020772 Hypertension Diseases 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
238000011282 treatment Methods 0.000 claims description 5
239000002552 dosage form Substances 0.000 claims description 4
239000002220 antihypertensive agent Substances 0.000 claims description 3
230000001631 hypertensive effect Effects 0.000 claims description 3
239000000523 sample Substances 0.000 claims description 3
229940127088 antihypertensive drug Drugs 0.000 claims description 2
229940079593 drug Drugs 0.000 claims description 2
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 2
229910052753 mercury Inorganic materials 0.000 claims description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
239000012153 distilled water Substances 0.000 claims 2
230000010349 pulsation Effects 0.000 claims 2
229940126062 Compound A Drugs 0.000 claims 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 1
238000009530 blood pressure measurement Methods 0.000 claims 1
230000001684 chronic effect Effects 0.000 claims 1
230000008034 disappearance Effects 0.000 claims 1
210000003734 kidney Anatomy 0.000 claims 1
229920000609 methyl cellulose Polymers 0.000 claims 1
239000001923 methylcellulose Substances 0.000 claims 1
235000010981 methylcellulose Nutrition 0.000 claims 1
210000002254 renal artery Anatomy 0.000 claims 1
229910052709 silver Inorganic materials 0.000 claims 1
239000004332 silver Substances 0.000 claims 1
230000035488 systolic blood pressure Effects 0.000 claims 1
230000003442 weekly effect Effects 0.000 claims 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 17
229960000830 captopril Drugs 0.000 description 16
239000003826 tablet Substances 0.000 description 13
239000002934 diuretic Substances 0.000 description 11
230000001882 diuretic effect Effects 0.000 description 10
239000000203 mixture Substances 0.000 description 9
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
239000008101 lactose Substances 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
229920002261 Corn starch Polymers 0.000 description 5
235000021355 Stearic acid Nutrition 0.000 description 5
239000008120 corn starch Substances 0.000 description 5
238000000034 method Methods 0.000 description 5
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
239000008117 stearic acid Substances 0.000 description 5
239000005541 ACE inhibitor Substances 0.000 description 4
229920001817 Agar Polymers 0.000 description 4
239000008272 agar Substances 0.000 description 4
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
239000013543 active substance Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
238000011699 spontaneously hypertensive rat Methods 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
FAKRSMQSSFJEIM-COBSHVIPSA-N (2r)-1-(2-methyl-3-sulfanylpropanoyl)pyrrolidine-2-carboxylic acid Chemical compound SCC(C)C(=O)N1CCC[C@@H]1C(O)=O FAKRSMQSSFJEIM-COBSHVIPSA-N 0.000 description 1
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
241000220479 Acacia Species 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
206010041277 Sodium retention Diseases 0.000 description 1
UUUHXMGGBIUAPW-CSCXCSGISA-N Teprotide Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCC(=O)N1 UUUHXMGGBIUAPW-CSCXCSGISA-N 0.000 description 1
108010045759 Teprotide Proteins 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
230000035619 diuresis Effects 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
238000007580 dry-mixing Methods 0.000 description 1
239000004744 fabric Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013305 food Nutrition 0.000 description 1
229940082195 hydrochlorothiazide 12.5 mg Drugs 0.000 description 1
229940082205 hydrochlorothiazide 25 mg Drugs 0.000 description 1
238000002513 implantation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
-1 mercapto-2-methylpropanoyl Chemical group 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229960002275 pentobarbital sodium Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
150000003147 proline derivatives Chemical class 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229950010186 teprotide Drugs 0.000 description 1
238000011706 wistar kyoto rat Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NL7812164A 1977-12-27 1978-12-14 Anti-hypertensief oraal farmaceutisch preparaat. NL192870C (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US86442877A	1977-12-27	1977-12-27
US86442877		1977-12-27

Publications (3)

Publication Number	Publication Date
NL7812164A NL7812164A (nl)	1979-06-29
NL192870B NL192870B (nl)	1997-12-01
NL192870C true NL192870C (nl)	1998-04-02

Family

ID=25343256

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NL7812164A NL192870C (nl)	1977-12-27	1978-12-14	Anti-hypertensief oraal farmaceutisch preparaat.
NL980017C NL980017I1 (nl)	1977-12-27	1998-04-24	Anti-hypertensief oraal farmaceutisch preparaat.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NL980017C NL980017I1 (nl)	1977-12-27	1998-04-24	Anti-hypertensief oraal farmaceutisch preparaat.

Country Status (30)

Country	Link
JP (1)	JPS54110333A (fr)
AR (1)	AR230378A1 (fr)
AU (1)	AU526239B2 (fr)
BE (1)	BE873092A (fr)
CA (1)	CA1120400A (fr)
CH (1)	CH642542A5 (fr)
DE (1)	DE2854316C3 (fr)
DK (1)	DK578778A (fr)
EG (1)	EG14178A (fr)
FI (1)	FI783991A7 (fr)
FR (1)	FR2413089A1 (fr)
GB (1)	GB2010675B (fr)
GR (1)	GR72951B (fr)
HK (1)	HK45483A (fr)
HU (1)	HU178747B (fr)
IE (1)	IE48306B1 (fr)
IL (1)	IL56281A (fr)
IT (1)	IT1202811B (fr)
KE (1)	KE3235A (fr)
LU (1)	LU80709A1 (fr)
MY (2)	MY8300240A (fr)
NL (2)	NL192870C (fr)
NO (1)	NO784357L (fr)
NZ (1)	NZ189159A (fr)
PH (1)	PH22111A (fr)
PL (1)	PL212188A1 (fr)
PT (1)	PT68983A (fr)
SE (1)	SE445173B (fr)
SG (1)	SG41482G (fr)
ZA (1)	ZA786948B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5829950B2 (ja) *	1978-10-05	1983-06-25	ウェルファイド株式会社	環状イミノカルボン酸誘導体およびその塩類
US4350704A (en)	1980-10-06	1982-09-21	Warner-Lambert Company	Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids
US4482725A (en) *	1980-04-03	1984-11-13	E. R. Squibb & Sons, Inc.	S-Acylation products of mercaptoacyl amino acids and carboxyl group containing diuretics
US4344949A (en)	1980-10-03	1982-08-17	Warner-Lambert Company	Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4532342A (en) *	1981-02-20	1985-07-30	Warner-Lambert Company	N-substituted amino acids as intermediates in the preparation of acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4552889A (en) *	1983-06-09	1985-11-12	Eli Lilly And Company	3-Mercaptomethyl-2-oxo-1-pyrrolidine acetic acids and use for hypertension
US4898729A (en) *	1983-12-09	1990-02-06	Euroceltique, S.A.	Treatment of hypertension, compounds and compositions for antihypertension and diuresis
DE3532036A1 (de) *	1985-09-09	1987-03-26	Hoechst Ag	Pharmazeutische zubereitung zur behandlung des bluthochdrucks
DK9200258U4 (da) *	1992-03-11	1993-07-23	Merck & Co Inc	Farmaceutisk præparat indeholdende enalapril til brug mod hypertension
WO1996024358A1 (fr) *	1995-02-10	1996-08-15	G.D. Searle & Co.	Utilisation de faibles doses de spironolactone dans le traitement de maladies cardio-vasculaires

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU509899B2 (en) *	1976-02-13	1980-05-29	E.R. Squibb & Sons, Inc.	Proline derivatives and related compounds

1978
- 1978-11-21 CA CA000316609A patent/CA1120400A/fr not_active Expired
- 1978-11-29 AU AU42041/78A patent/AU526239B2/en not_active Expired
- 1978-12-06 IE IE2413/78A patent/IE48306B1/en unknown
- 1978-12-06 FR FR7834359A patent/FR2413089A1/fr active Granted
- 1978-12-12 ZA ZA786948A patent/ZA786948B/xx unknown
- 1978-12-13 NZ NZ189159A patent/NZ189159A/en unknown
- 1978-12-14 GR GR57879A patent/GR72951B/el unknown
- 1978-12-14 CH CH1273778A patent/CH642542A5/de not_active IP Right Cessation
- 1978-12-14 NL NL7812164A patent/NL192870C/nl not_active IP Right Cessation
- 1978-12-15 DE DE2854316A patent/DE2854316C3/de not_active Expired - Lifetime
- 1978-12-19 PH PH21971A patent/PH22111A/en unknown
- 1978-12-21 GB GB7849703A patent/GB2010675B/en not_active Expired
- 1978-12-22 DK DK578778A patent/DK578778A/da not_active Application Discontinuation
- 1978-12-22 HU HU78SU1000A patent/HU178747B/hu unknown
- 1978-12-22 IT IT31266/78A patent/IT1202811B/it active Protection Beyond IP Right Term
- 1978-12-22 IL IL56281A patent/IL56281A/xx unknown
- 1978-12-22 LU LU80709A patent/LU80709A1/de unknown
- 1978-12-22 NO NO784357A patent/NO784357L/no unknown
- 1978-12-22 SE SE7813277A patent/SE445173B/sv not_active IP Right Cessation
- 1978-12-25 EG EG740/78A patent/EG14178A/xx active
- 1978-12-25 JP JP16462778A patent/JPS54110333A/ja active Granted
- 1978-12-26 PT PT68983A patent/PT68983A/pt unknown
- 1978-12-27 AR AR274975A patent/AR230378A1/es active
- 1978-12-27 PL PL21218878A patent/PL212188A1/xx unknown
- 1978-12-27 BE BE192574A patent/BE873092A/fr not_active IP Right Cessation
- 1978-12-27 FI FI783991A patent/FI783991A7/fi unknown
1982
- 1982-09-02 SG SG414/82A patent/SG41482G/en unknown
- 1982-09-14 KE KE3235A patent/KE3235A/xx unknown
1983
- 1983-10-20 HK HK454/83A patent/HK45483A/xx not_active IP Right Cessation
- 1983-12-30 MY MY240/83A patent/MY8300240A/xx unknown
1987
- 1987-10-31 MY MYPI87003001A patent/MY102991A/en unknown
1998
- 1998-04-24 NL NL980017C patent/NL980017I1/nl unknown

Also Published As

Publication number	Publication date
CA1120400A (fr)	1982-03-23
SG41482G (en)	1985-01-11
GR72951B (fr)	1984-01-17
IT1202811B (it)	1989-02-09
PL212188A1 (fr)	1980-02-11
GB2010675A (en)	1979-07-04
PH22111A (en)	1988-06-01
HK45483A (en)	1983-10-28
JPS54110333A (en)	1979-08-29
IL56281A (en)	1983-05-15
IL56281A0 (en)	1979-03-12
MY8300240A (en)	1983-12-31
GB2010675B (en)	1982-06-16
DK578778A (da)	1979-06-28
AR230378A1 (es)	1984-04-30
FI783991A7 (fi)	1979-06-28
NO784357L (no)	1979-06-28
AU526239B2 (en)	1982-12-23
SE445173B (sv)	1986-06-09
KE3235A (en)	1982-11-05
AU4204178A (en)	1979-07-05
EG14178A (en)	1984-06-30
NL192870B (nl)	1997-12-01
IT7831266A0 (it)	1978-12-22
CH642542A5 (de)	1984-04-30
NZ189159A (en)	1984-12-14
JPS647045B2 (fr)	1989-02-07
MY102991A (en)	1993-03-31
DE2854316C3 (de)	1994-12-22
NL980017I1 (nl)	1998-07-01
NL7812164A (nl)	1979-06-29
DE2854316A1 (de)	1979-07-05
PT68983A (en)	1979-01-01
DE2854316C2 (fr)	1989-08-10
LU80709A1 (de)	1979-04-13
HU178747B (en)	1982-06-28
IE782413L (en)	1979-06-27
FR2413089A1 (fr)	1979-07-27
IE48306B1 (en)	1984-12-12
BE873092A (fr)	1979-06-27
FR2413089B1 (fr)	1980-12-26
SE7813277L (sv)	1979-06-28
ZA786948B (en)	1980-04-30

Legal Events

Date	Code	Title	Description
1985-01-01	A85	Still pending on 85-01-01
1986-02-03	BA	A request for search or an international-type search has been filed
1986-02-03	BB	A search report has been drawn up
1986-07-01	BC	A request for examination has been filed
1998-07-01	AC1	Application for a supplementary protection certificate	Free format text: 980017, 980424
1998-11-02	BC1	Further communications concerning applications for a supplementary protection certificate	Free format text: 980017
1999-02-01	BC1	Further communications concerning applications for a supplementary protection certificate	Free format text: 980017
1999-02-01	V4	Discontinued because of reaching the maximum lifetime of a patent	Free format text: 981214

Publication	Publication Date	Title
US4217347A (en)	1980-08-12	Method of treating hypertension and medicaments therefor
US4746668A (en)	1988-05-24	Method for treating retinopathy
US20030216384A1 (en)	2003-11-20	Composition and method for treating hypertension
EP0629400B1 (fr)	1999-09-22	Compositions contenant de l'idebenone pour le traitement de la maladie d'Alzheimer
Onesti et al.	1962	Pharmacodynamic effects and clinical use of alpha methyldopa in the treatment of essential hypertension∗
HUP0300917A2 (hu)	2003-08-28	Bradikardiakumok alkalmazása hipertrófiával társult miokardiális betegségek kezelésére és ezeket tartalmazó gyógyszerkészítmények
Plänitz	1987	Comparison of moxonidine and clonidine HCl in treating patients with hypertension
DE69712338T2 (de)	2002-11-07	Zusammensetzung auf basis von enalapril und losartan
WO2001056609A1 (fr)	2001-08-09	Composition pharmaceutique destinee au traitement d'une hyperhomocysteinemie provoquee par un medicament
EP0005015B1 (fr)	1986-10-29	Utilisation d'un dérivé de xanthine dans la fabrication d'un médicament
CN102327272A (zh)	2012-01-25	一种全新口服固体药用组合物及其制备方法
NZ189159A (en)	1984-12-14	Oral antihypertensive compositions containing proline derivatives
CA2870373A1 (fr)	2013-10-17	Preparation composee constituee de chlorhydrate de lercanidipine et de losartan potassique et son procede de preparation
US4225607A (en)	1980-09-30	Pharmaceutical composition containing a xanthine derivative
JPS626687B2 (fr)	1987-02-13
JP2584636B2 (ja)	1997-02-26	胃炎治療剤
DE3888827T2 (de)	1994-07-14	Behandlung von arteriosklerosis durch verabreichung von l-tryptophane oder l-5-hydroxytryptophan.
JPH0251885B2 (fr)	1990-11-08
JPS58140017A (ja)	1983-08-19	心不全治療剤
JP3024789B2 (ja)	2000-03-21	血圧降下剤
Wiseman et al.	1968	Development of a sustained‐release aspirin tablet
EP0576452B1 (fr)	1994-11-09	Produits contenant du verapamil et du trandolapril
KR20010019397A (ko)	2001-03-15	발기부전 치료용 조성물
GB2141027A (en)	1984-12-12	Diltiazem hypolipidemic compositions
RU2183117C1 (ru)	2002-06-10	Средство для нормализации артериального давления и способ лечения гипертонической болезни